From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease.
about
Adenosine and hypoxia-inducible factor signaling in intestinal injury and recoveryPurinergic Signaling in Gut Inflammation: The Role of Connexins and PannexinsDisrupted regulatory T cell homeostasis in inflammatory bowel diseasesThe role of macrophages and dendritic cells in the initiation of inflammation in IBDDevelopment and survival of Th17 cells within the intestines: the influence of microbiome- and diet-derived signalsNew era for mucosal mast cells: their roles in inflammation, allergic immune responses and adjuvant developmentPotential for developing purinergic drugs for gastrointestinal diseasesThe Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host DiseaseExtracellular adenosine regulates colitis through effects on lymphoid and nonlymphoid cells.The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology.Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39.CD39/adenosine pathway is involved in AIDS progressionPurinergic signaling during inflammation.Adenosine signaling during acute and chronic disease statesExtracellular nucleotide and nucleoside signaling in vascular and blood diseaseExpression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection.Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors.The resurgence of A2B adenosine receptor signalingNucleotide signalling during inflammationNTPDase1 governs P2X7-dependent functions in murine macrophagesBiological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states.A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine productionCharacterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel diseasePathophysiological role of extracellular purinergic mediators in the control of intestinal inflammation.Diet- and Genetically-Induced Obesity Differentially Affect the Fecal Microbiome and Metabolome in Apc1638N MiceLongitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal.Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis.Transgenic swine: expression of human CD39 protects against myocardial injury.Autoimmune Hepatitis: Clinical Review with Insights into the Purinergic Mechanism of DiseaseEctonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice.Epithelial-specific A2B adenosine receptor signaling protects the colonic epithelial barrier during acute colitisInterface between hemostasis and adaptive immunityA commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg functionE-NPP3 controls plasmacytoid dendritic cell numbers in the small intestineCD73 is critical for the resolution of murine colonic inflammationNADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine.Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantationAdequate Dextran Sodium Sulfate-induced Colitis Model in Mice and Effective Outcome Measurement MethodExtracellular ATP mediates inflammatory responses in colitis via P2 × 7 receptor signaling
P2860
Q24620924-A7FDFAF2-9FBF-43C0-9AAE-9754103BB0D1Q26738433-940732F4-1B34-4F17-95B9-85ED6853F3CEQ26774590-AF83B67A-780C-4E4F-A2C6-933986AA33CEQ26827408-D79B1E70-3FD6-4EB9-AFE4-2977FE8B3103Q26829933-9EA371DE-5F7A-46CD-B38B-316024046E75Q26864415-1D45C115-EACC-4C6A-A1D7-F83EA11B36B5Q27000719-495E0E18-0838-41A1-AEF3-1DD85EB05250Q28068647-213EC307-ED3D-42F2-832B-DA097363F4A7Q30371536-CCA05A34-ECF1-4206-8728-81F6F3521902Q30426440-57E03911-1BF7-41FB-A88F-F24182AAB3CEQ30433245-1BA92355-E3FA-47F2-9B8A-CFEEC4EC0B4FQ33889692-37B2EB1E-2190-4B94-BC9B-7B4525DFBC63Q33959186-B184578A-4057-40E8-B9F6-3FBBA87EC220Q34034751-DD9AE8B4-B20E-432E-9C65-FA5C3EEC2D04Q34035228-CCD794B1-2AB8-4EF2-AC91-41AB01A571E4Q34047834-06100204-C5A5-468C-B3DA-D9EE0AAAC87BQ34226860-095A5112-9D7C-49CB-9411-9939C5DBA1BDQ34297567-B36F4352-8D72-40CD-8761-1DF9AE1786EDQ34307284-35F26A62-5CF8-40E7-B5CA-7190026726D4Q34464511-B45E1714-FA37-44F6-8CBD-0BCA8F98239BQ34610192-F0DD306F-D1E2-4A37-989A-A55A8A58AAAFQ34703746-D994DE0C-E63C-4206-ADEE-DF9BEB1DD64BQ35064373-C57D86C2-6B2D-40FD-86E0-85396E79F4E9Q35088318-25568E5F-D271-43C6-A451-FECB47128627Q35511015-42C6F5F8-C8EA-4161-A137-DDB044A5A32BQ35748788-EDDAD5A3-DADE-4F35-916C-5F6B112D8C3AQ35825015-A5ABFEA1-25AD-4F78-BA45-D064ED4758A4Q35874789-B59E2727-D12E-4BF3-B25C-FD3A03D1260BQ35892406-1C8E361C-FC6B-47E6-BBD8-07913438C95FQ35906055-071E191C-84D2-40AA-9BF8-B3AD8191CAD6Q36071796-D151561D-A3A7-4383-89C3-53C3CB5345CAQ36137545-6D32F208-A17E-4103-A71E-94814053FE92Q36190599-4765A042-A0E7-43F6-91CA-DF7DA603DBC5Q36191738-371380EC-F031-4A01-9ECD-A38B11899637Q36287519-6385156A-3FE0-4F1E-A4D6-7AEEACC8D4A3Q36336800-5FA44040-E010-4D4C-9D18-38502A9E331BQ36341390-D150A0AC-57F6-4049-8D4E-5146145077EBQ36350059-26CAE3F7-241E-470F-AC37-6DE223BD40E8Q36426111-F60C0C2C-FBE8-4E4E-9287-D8ED5184078AQ36438334-C381FE63-564C-4977-88F8-8848C491091F
P2860
From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
From the Cover: CD39 deletion ...... to inflammatory bowel disease.
@en
From the Cover: CD39 deletion ...... to inflammatory bowel disease.
@nl
type
label
From the Cover: CD39 deletion ...... to inflammatory bowel disease.
@en
From the Cover: CD39 deletion ...... to inflammatory bowel disease.
@nl
prefLabel
From the Cover: CD39 deletion ...... to inflammatory bowel disease.
@en
From the Cover: CD39 deletion ...... to inflammatory bowel disease.
@nl
P2093
P2860
P356
P1476
From the Cover: CD39 deletion ...... to inflammatory bowel disease.
@en
P2093
Beat M Künzli
David J Friedman
Jean Sevigny
Keiichi Enjyoji
Pascal O Berberat
Simon C Robson
Yousif I A-Rahim
P2860
P304
16788-16793
P356
10.1073/PNAS.0902869106
P407
P577
2009-09-28T00:00:00Z